{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:47:20Z","timestamp":1792396040862,"version":"4.4.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"9-10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Med"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.2119\/molmed.2011.00145","type":"journal-article","created":{"date-parts":[[2011,10,7]],"date-time":"2011-10-07T21:26:59Z","timestamp":1318022819000},"page":"1000-1011","source":"Crossref","is-referenced-by-count":58,"title":["\u03b1-1-Antitrypsin Gene Delivery Reduces Inflammation, Increases T-Regulatory Cell Population Size and Prevents Islet Allograft Rejection"],"prefix":"10.1186","volume":"17","author":[{"given":"Galit","family":"Shahaf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas","family":"Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Ozeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Mizrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avishag","family":"Abecassis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli C.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,6,9]]},"reference":[{"key":"1791000_CR1","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1056\/NEJMoa052187","volume":"353","author":"DM Nathan","year":"2005","unstructured":"Nathan DM, et al. (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353:2643\u201353.","journal-title":"N. Engl. J. Med."},{"key":"1791000_CR2","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.2337\/db09-1846","volume":"59","author":"RP Robertson","year":"2010","unstructured":"Robertson RP. (2010) Islet transplantation a decade later and strategies for filling a half-full glass. Diabetes. 59:1285\u201391.","journal-title":"Diabetes"},{"key":"1791000_CR3","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s11892-010-0138-y","volume":"10","author":"J Ludvigsson","year":"2010","unstructured":"Ludvigsson J. (2010) Immune intervention in children with type 1 diabetes. Curr Diab Rep 10:370\u20139.","journal-title":"Curr Diab Rep"},{"key":"1791000_CR4","first-page":"678","volume":"11","author":"O Leavy","year":"2011","unstructured":"Leavy O. (2011) Autoimmunity: joint damage without antigen. Nat. Rev. Immunol. 11:678.","journal-title":"Nat. Rev. Immunol."},{"key":"1791000_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.bbadis.2010.07.007","volume":"2011","author":"C Stadelmann","year":"2011","unstructured":"Stadelmann C, Wegner C, Bruck W. (2011) Inflammation, demyelination, and degeneration: recent insights from MS pathology. Biochim. Biophys. Acta. 2011:275\u201382.","journal-title":"Biochim. Biophys. Acta."},{"key":"1791000_CR6","first-page":"135","volume":"11","author":"T Gambichler","year":"2006","unstructured":"Gambichler T, et al. (2006) Complex extraintestinal complications of ulcerative colitis in a patient with alpha1-antitrypsin deficiency. Eur. J. Med. Res. 11:135\u20138.","journal-title":"Eur. J. Med. Res."},{"key":"1791000_CR7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0025-6196(11)64212-2","volume":"75","author":"P Yang","year":"2000","unstructured":"Yang P, et al. (2000) Alpha1-antitrypsin deficiency and inflammatory bowel diseases. Mayo Clin. Proc. 75:450\u20135.","journal-title":"Mayo Clin. Proc."},{"key":"1791000_CR8","first-page":"26","volume":"4","author":"XH Zhang","year":"1989","unstructured":"Zhang XH, et al. (1989) Changes of neutrophil elastase and alpha 1-antitrypsin in systemic lupus erythematosus. Proc. Chin. Acad. Med. Sci. Peking Union Med. Coll. 4:26\u20139.","journal-title":"Proc. Chin. Acad. Med. Sci. Peking Union Med. Coll."},{"key":"1791000_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00281-011-0251-2","volume":"33","author":"DR Goldstein","year":"2011","unstructured":"Goldstein DR. (2011) Inflammation and transplantation tolerance. Semin. Immunopathol. 33:111\u20135.","journal-title":"Semin. Immunopathol."},{"key":"1791000_CR10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/MOT.0b013e32833b7929","volume":"15","author":"D Hanidziar","year":"2010","unstructured":"Hanidziar D, Koulmanda M. (2010) Inflammation and the balance of Treg and Th17 cells in transplant rejection and tolerance. Curr. Opin. Organ Transplant. 15:411\u201315.","journal-title":"Curr. Opin. Organ Transplant"},{"key":"1791000_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/BF02427283","volume":"29","author":"T Mandrup-Poulsen","year":"1986","unstructured":"Mandrup-Poulsen T, et al. (1986) Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia. 29:63\u20137.","journal-title":"Diabetologia"},{"key":"1791000_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/jcp.21770","volume":"220","author":"A Schwarznau","year":"2009","unstructured":"Schwarznau A, et al. (2009) IL-1beta receptor blockade protects islets against pro-inflammatory cytokine induced necrosis and apoptosis. J. Cell Physiol. 220:341\u20137.","journal-title":"J. Cell Physiol."},{"key":"1791000_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/1043-4666(93)90003-N","volume":"5","author":"T Mandrup-Poulsen","year":"1993","unstructured":"Mandrup-Poulsen T, et al. (1993) Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic beta-cell destruction in insulin-dependent diabetes mellitus. Cytokine. 5:185\u201391.","journal-title":"Cytokine"},{"key":"1791000_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3727\/000000004783983611","volume":"13","author":"MF Solomon","year":"2004","unstructured":"Solomon MF, Kuziel WA, Simeonovic CJ. (2004) The contribution of chemokines and chemokine receptors to the rejection of fetal proislet allografts. Cell Transplant. 13:503\u201314.","journal-title":"Cell Transplant"},{"key":"1791000_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2337\/diabetes.51.1.55","volume":"51","author":"L Piemonti","year":"2002","unstructured":"Piemonti L, et al. (2002) Human pancreatic islets produce and secrete MCP-1\/CCL2: relevance in human islet transplantation. Diabetes. 51:55\u201365.","journal-title":"Diabetes"},{"key":"1791000_CR16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s001250051622","volume":"44","author":"MC Chen","year":"2001","unstructured":"Chen MC, et al. (2001) Monocyte chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice and in interleukin-1 betaexposed human and rat islet cells. Diabetologia. 44:325\u201332.","journal-title":"Diabetologia"},{"key":"1791000_CR17","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1084\/jem.178.5.1629","volume":"178","author":"H Tilg","year":"1993","unstructured":"Tilg H, et al. (1993) Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells. J. Exp. Med. 178:1629\u201336.","journal-title":"J. Exp. Med."},{"key":"1791000_CR18","doi-asserted-by":"publisher","first-page":"12153","DOI":"10.1073\/pnas.0505579102","volume":"102","author":"EC Lewis","year":"2005","unstructured":"Lewis EC, et al. (2005) Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice. Proc. Natl. Acad. Sci. U. S. A. 102:12153\u20138.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"1791000_CR19","doi-asserted-by":"publisher","first-page":"16236","DOI":"10.1073\/pnas.0807627105","volume":"105","author":"EC Lewis","year":"2008","unstructured":"Lewis EC, et al. (2008) Alpha1-antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc. Natl. Acad. Sci. U. S. A. 105:16236\u201341.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"1791000_CR20","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/labinvest.3780324","volume":"81","author":"A Churg","year":"2001","unstructured":"Churg A, et al. (2001) Alpha-1-antitrypsin and a broad spectrum metalloprotease inhibitor, RS113456, have similar acute anti-inflammatory effects. Lab. Invest. 81:1119\u201331.","journal-title":"Lab. Invest."},{"key":"1791000_CR21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00011-010-0164-x","volume":"59","author":"D Subramaniyam","year":"2010","unstructured":"Subramaniyam D, et al. (2010) Effects of alpha 1-antitrypsin on endotoxin-induced lung inflammation in vivo. Inflamm. Res. 59:571\u20138.","journal-title":"Inflamm. Res."},{"key":"1791000_CR22","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.biocel.2007.02.017","volume":"39","author":"IM Nita","year":"2007","unstructured":"Nita IM, Serapinas D, Janciauskiene SM. (2007) Alpha1-antitrypsin regulates CD14 expression and soluble CD14 levels in human monocytes in vitro. Int. J. Biochem. Cell Biol. 39:1165\u201376.","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"1791000_CR23","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.biocel.2010.06.009","volume":"42","author":"D Subramaniyam","year":"2010","unstructured":"Subramaniyam D, et al. (2010) Cholesterol rich lipid raft microdomains are gateway for acute phase protein, SERPINA1. Int. J. Biochem. Cell Biol. 42:1562\u201370.","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"1791000_CR24","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1172\/JCI41196","volume":"120","author":"DA Bergin","year":"2010","unstructured":"Bergin DA, et al. (2010) Alpha-1 antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J. Clin. Invest. 120:4236\u201350.","journal-title":"J. Clin. Invest."},{"key":"1791000_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1479-5876-9-21","volume":"9","author":"C Grimstein","year":"2011","unstructured":"Grimstein C, et al. (2011) Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model. J. Transi. Med. 9:21.","journal-title":"J. Transi. Med."},{"key":"1791000_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11011-011-9239-9","volume":"26","author":"S Subramanian","year":"2011","unstructured":"Subramanian S, Shahaf G, Ozeri E, et al. (2011) Sustained expression of circulating human alpha-1 antitrypsin reduces inflammation, increases CD4+FoxP3+ Treg cell population and prevents signs of experimental autoimmune encephalomyelitis in mice. Metab. Brain Dis. 26:107\u201313.","journal-title":"Metab. Brain Dis."},{"key":"1791000_CR27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/096120339500400311","volume":"4","author":"JK Lacki","year":"1995","unstructured":"Lacki JK, et al. (1995) IgA-alpha-1-antitrypsin complex in systemic lupus erythematosus: preliminary report. Lupus. 4:221\u20131.","journal-title":"Lupus"},{"key":"1791000_CR28","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/00054725-199911000-00002","volume":"5","author":"AN Elzouki","year":"1999","unstructured":"Elzouki AN, et al. (1999) The prevalence and clinical significance of alpha 1-antitrypsin deficiency (PiZ) and ANCA specificities (proteinase 3, BPI) in patients with ulcerative colitis. Inflamm. Bowel Dis. 5:246\u201352.","journal-title":"Inflamm. Bowel Dis."},{"key":"1791000_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2217\/imt.10.40","volume":"2","author":"M Koulmanda","year":"2010","unstructured":"Koulmanda M, Strom TB. (2010) T-cell-directed treatment strategies for type 1 diabetes and the confounding role of inflammation. Immunotherapy. 2:431\u20136.","journal-title":"Immunotherapy"},{"key":"1791000_CR30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.transproceed.2008.02.010","volume":"40","author":"A Pileggi","year":"2008","unstructured":"Pileggi A, et al. (2008) Alpha-1 antitrypsin treatment of spontaneously diabetic nonobese diabetic mice receiving islet allografts prolonged islet allograft survival by alpha-1 antitrypsin: the role of humoral immunity. Transplant Proc. 40:457\u20138.","journal-title":"Transplant Proc."},{"key":"1791000_CR31","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1007\/s00125-010-1829-2","volume":"53","author":"H Ma","year":"2010","unstructured":"Ma H, et al. (2010) Intradermal alpha1-antitrypsin therapy avoids fatal anaphylaxis, prevents type 1 diabetes and reverses hyperglycaemia in the NOD mouse model of the disease. Diabetologia. 53:2198\u2013204.","journal-title":"Diabetologia"},{"key":"1791000_CR32","doi-asserted-by":"publisher","first-page":"16242","DOI":"10.1073\/pnas.0808031105","volume":"105","author":"M Koulmanda","year":"2008","unstructured":"Koulmanda M, et al. (2008) Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc. Natl. Acad. Sci. U. S. A. 105:16242\u20137.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"1791000_CR33","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11892-009-0018-5","volume":"9","author":"GC Weir","year":"2009","unstructured":"Weir GC, Koulamnda M. (2009) Control of inflammation with alpha1-antitrypsin: a potential treatment for islet transplantation and new-onset type 1 diabetes. Curr. Diab. Rep. 9:100\u20132.","journal-title":"Curr. Diab. Rep."},{"key":"1791000_CR34","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/j.1600-0404.1995.tb07027.x","volume":"91","author":"YI Lolin","year":"1995","unstructured":"Lolin YI, Ward AM. (1995) Alpha-1-antitrypsin phenotypes and associated disease patterns in neurological patients. Acta. Neurol. Scand. 91:394\u20138.","journal-title":"Acta. Neurol. Scand."},{"key":"1791000_CR35","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/sj.gt.3302156","volume":"11","author":"S Song","year":"2004","unstructured":"Song S, et al. (2004) Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice. Gene Ther. 11:181\u20136.","journal-title":"Gene Ther."},{"key":"1791000_CR36","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4161\/isl.2.3.11654","volume":"2","author":"M Kalis","year":"2010","unstructured":"Kalis M, et al. (2010) Alpha 1-antitrypsin enhances insulin secretion and prevents cytokinemediated apoptosis in pancreatic beta-cells. Islets. 2:185\u20139.","journal-title":"Islets"},{"key":"1791000_CR37","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/j.transproceed.2010.05.119","volume":"42","author":"G Loganathan","year":"2010","unstructured":"Loganathan G, et al. (2010) Culture of impure human islet fractions in the presence of alpha-1 antitrypsin prevents insulin cleavage and improves islet recovery. Transplant. Proc. 42:2055\u20137.","journal-title":"Transplant. Proc."},{"key":"1791000_CR38","doi-asserted-by":"publisher","first-page":"16236","DOI":"10.1073\/pnas.0807627105","volume":"105","author":"EC Lewis","year":"2008","unstructured":"Lewis EC, et al. (2008) Alpha1-antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc. Natl. Acad. Sci. U. S. A. 105:16236\u201341.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"1791000_CR39","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.thromres.2009.05.020","volume":"124","author":"D Hernandez-Espinosa","year":"2009","unstructured":"Hernandez-Espinosa D, et al. (2009) Hyperglycaemia impairs antithrombin secretion: possible contribution to the thrombotic risk of diabetes. Thromb. Res. 124:483\u201389.","journal-title":"Thromb. Res."},{"key":"1791000_CR40","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s00592-006-0220-8","volume":"43","author":"B Lisowska-Myjak","year":"2006","unstructured":"Lisowska-Myjak B, et al. (2006) Serum protease inhibitor concentrations and total antitrypsin activity in diabetic and non-diabetic children during adolescence. Acta Diabetol. 43:88\u201392.","journal-title":"Acta Diabetol."},{"key":"1791000_CR41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.diabres.2009.03.003","volume":"84","author":"M Yaghmaei","year":"2009","unstructured":"Yaghmaei M, et al. (2009) Serum trypsin inhibitory capacity in normal pregnancy and gestational diabetes mellitus. Diabetes Res. Clin. Pract. 84:201\u20134.","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1791000_CR42","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.diabres.2006.06.020","volume":"75","author":"M Hashemi","year":"2007","unstructured":"Hashemi M, et al. (2007) Impaired activity of serum alpha-1-antitrypsin in diabetes mellitus. Diabetes Res. Clin. Pract. 75:246\u20138.","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1791000_CR43","first-page":"178","volume":"69","author":"I Blanco","year":"2008","unstructured":"Blanco I, et al. (2008) Long-term augmentation therapy with alpha-1 antitrypsin in an MZ-AAT severe persistent asthma. Monaldi Arch. Chest Dis. 69:178\u201382.","journal-title":"Monaldi Arch. Chest Dis."},{"key":"1791000_CR44","first-page":"193","volume":"3","author":"I Petrache","year":"2009","unstructured":"Petrache I, Hajjar J, Campos M. (2009) Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency. Biologics. 3:193\u2013204.","journal-title":"Biologics"},{"key":"1791000_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S0002-9343(88)80071-8","volume":"84","author":"RC Hubbard","year":"1988","unstructured":"Hubbard RC, Crystal RG. (1988) Alpha-1-antitrypsin augmentation therapy for alpha-1-antitrypsin deficiency. Am. J. Med. 84:52\u201362.","journal-title":"Am. J. Med."},{"key":"1791000_CR46","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1517\/14656566.8.15.2609","volume":"8","author":"NM Mordwinkin","year":"2007","unstructured":"Mordwinkin NM, Louie SG. (2007) Aralast: an alpha 1-protease inhibitor for the treatment of alpha-antitrypsin deficiency. Expert Opin. Pharmacother. 8:2609\u2013614.","journal-title":"Expert Opin. Pharmacother."},{"key":"1791000_CR47","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1345\/aph.1E061","volume":"39","author":"SG Louie","year":"2005","unstructured":"Louie SG, Sclar DA, Gill MA. (2005) Aralast: a new alpha1-protease inhibitor for treatment of alpha-antitrypsin deficiency. Ann. Pharmacother. 39:1861\u20139.","journal-title":"Ann. Pharmacother."},{"key":"1791000_CR48","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1006\/mthe.2001.0429","volume":"4","author":"SM Stoll","year":"2001","unstructured":"Stoll SM, et al. (2001) Epstein-Barr virus\/human vector provides high-level, long-term expression of alpha1-antitrypsin in mice. Mol. Ther. 4:122\u20139.","journal-title":"Mol. Ther."},{"key":"1791000_CR49","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s001090050364","volume":"77","author":"R Dhami","year":"1999","unstructured":"Dhami R, et al. (1999) Pulmonary epithelial expression of human alpha1-antitrypsin in transgenic mice results in delivery of alpha1-antitrypsin protein to the interstitium. J. Mol. Med. 77:377\u201385.","journal-title":"J. Mol. Med."},{"key":"1791000_CR50","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.exphem.2009.02.004","volume":"37","author":"HB Kuiperij","year":"2009","unstructured":"Kuiperij HB, et al. (2009) Serpina1 (alpha1-AT) is synthesized in the osteoblastic stem cell niche. Exp. Hematol. 37:641\u20137.","journal-title":"Exp. Hematol."},{"key":"1791000_CR51","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0009-8981(96)06379-6","volume":"254","author":"N Seta","year":"1996","unstructured":"Seta N, et al. (1996) Diagnostic value of Western blotting in carbohydrate-deficient glycoprotein syndrome. Clin. Chim. Acta. 254:131\u201340.","journal-title":"Clin. Chim. Acta."},{"key":"1791000_CR52","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1183\/09031936.97.10030672","volume":"10","author":"DA Lomas","year":"1997","unstructured":"Lomas DA, Elliott PR, Carrell RW. (1997) Commercial plasma alpha1-antitrypsin (Prolastin) contains a conformationally inactive, latent component. Eur. Respir. J. 10:672\u20135.","journal-title":"Eur. Respir. J."},{"key":"1791000_CR53","doi-asserted-by":"publisher","first-page":"793","DOI":"10.4049\/jimmunol.182.2.793","volume":"182","author":"S Walters","year":"2009","unstructured":"Walters S, et al. (2009) Increased CD4+Foxp3+ T cells in BAFF-transgenic mice suppress T cell effector responses. J. Immunol. 182:793\u2013801.","journal-title":"J. Immunol."},{"key":"1791000_CR54","doi-asserted-by":"publisher","first-page":"6929","DOI":"10.4049\/jimmunol.171.12.6929","volume":"171","author":"I Lee","year":"2003","unstructured":"Lee I, et al. (2003) Blocking the monocyte chemoattractant protein-1\/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism. J. Immunol. 171:6929\u201335.","journal-title":"J. Immunol."},{"key":"1791000_CR55","doi-asserted-by":"publisher","first-page":"16242","DOI":"10.1073\/pnas.0808031105","volume":"105","author":"M Koulmanda","year":"2008","unstructured":"Koulmanda M, et al. (2008) Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc. Natl. Acad. Sci. U. S. A. 105:16242\u20137.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"1791000_CR56","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.transproceed.2008.02.009","volume":"40","author":"RD Molano","year":"2008","unstructured":"Molano RD, et al. (2008) Prolonged islet allograft survival by alpha-1 antitrypsin: the role of humoral immunity. Transplant. Proc. 40:455\u20136.","journal-title":"Transplant. Proc."},{"key":"1791000_CR57","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.2337\/db06-1273","volume":"56","author":"B Zhang","year":"2007","unstructured":"Zhang B, et al. (2007) Alpha1-antitrypsin protects beta-cells from apoptosis. Diabetes. 56:1316\u201323.","journal-title":"Diabetes"},{"key":"1791000_CR58","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1089\/hum.2006.17.625","volume":"17","author":"Y Lu","year":"2006","unstructured":"Lu Y, et al. (2006) Alpha1-antitrypsin gene therapy modulates cellular immunity and efficiently prevents type 1 diabetes in nonobese diabetic mice. Hum. Gene Ther. 17:625\u201334.","journal-title":"Hum. Gene Ther."},{"key":"1791000_CR59","doi-asserted-by":"publisher","first-page":"16236","DOI":"10.1073\/pnas.0807627105","volume":"105","author":"EC Lewis","year":"2008","unstructured":"Lewis EC, et al. (2008) Alpha1-antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc. Natl. Acad. Sci. U. S. A. 105:16236\u201341.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"1791000_CR60","doi-asserted-by":"publisher","first-page":"12153","DOI":"10.1073\/pnas.0505579102","volume":"102","author":"EC Lewis","year":"2005","unstructured":"Lewis EC, et al. (2005) Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice. Proc. Natl. Acad. Sci. U. S. A. 102:12153\u20138.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"1791000_CR61","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1042\/bst0300093","volume":"30","author":"N Kalsheker","year":"2002","unstructured":"Kalsheker N, Morley S, Morgan K. (2002) Gene regulation of the serine proteinase inhibitors alpha1-antitrypsin and alpha1-antichymotrypsin. Biochem. Soc. Trans. 30:93\u20138.","journal-title":"Biochem. Soc. Trans."},{"key":"1791000_CR62","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.2217\/14622416.8.9.1191","volume":"8","author":"PE Cruz","year":"2007","unstructured":"Cruz PE, Mueller C, Flotte TR. (2007) The promise of gene therapy for the treatment of alpha-1 antitrypsin deficiency. Pharmacogenomics. 8:1191\u20138.","journal-title":"Pharmacogenomics"},{"key":"1791000_CR63","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/sj.gt.3301229","volume":"7","author":"G Zhang","year":"2000","unstructured":"Zhang G, Song YK, Liu D. (2000) Long-term expression of human alpha1-antitrypsin gene in mouse liver achieved by intravenous administration of plasmid DNA using a hydrodynamicsbased procedure. Gene Ther. 7:1344\u20139.","journal-title":"Gene Ther."},{"key":"1791000_CR64","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/sj.gt.3303079","volume":"15","author":"JW Fabre","year":"2008","unstructured":"Fabre JW, et al. (2008) Hydrodynamic gene delivery to the pig liver via an isolated segment of the inferior vena cava. Gene Ther. 15:452\u201362.","journal-title":"Gene Ther."},{"key":"1791000_CR65","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/sj.gt.3302833","volume":"13","author":"H Yoshino","year":"2006","unstructured":"Yoshino H, Hashizume K, Kobayashi E. (2006) Naked plasmid DNA transfer to the porcine liver using rapid injection with large volume. Gene Ther. 13:1696\u2013702.","journal-title":"Gene Ther."},{"key":"1791000_CR66","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/sj.gt.3302873","volume":"14","author":"SF Alino","year":"2007","unstructured":"Alino SF, et al. (2007) Pig liver gene therapy by noninvasive interventionist catheterism. Gene Ther. 14:334\u201343.","journal-title":"Gene Ther."},{"key":"1791000_CR67","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/sj.cgt.7701119","volume":"15","author":"SE Khorsandi","year":"2008","unstructured":"Khorsandi SE, et al. (2008) Minimally invasive and selective hydrodynamic gene therapy of liver segments in the pig and human. Cancer Gene Ther. 15:225\u201330.","journal-title":"Cancer Gene Ther."},{"key":"1791000_CR68","doi-asserted-by":"publisher","first-page":"5724","DOI":"10.1210\/jc.2004-0659","volume":"89","author":"F Bertuzzi","year":"2004","unstructured":"Bertuzzi F, et al. (2004) Tissue factor and CCL2\/monocyte chemoattractant protein-1 released by human islets affect islet engraftment in type 1 diabetic recipients. J. Clin. Endocrinol. Metab. 89:5724\u20138.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1791000_CR69","doi-asserted-by":"publisher","first-page":"767","DOI":"10.4049\/jimmunol.172.2.767","volume":"172","author":"R Abdi","year":"2004","unstructured":"Abdi R, et al. (2004) Differential role of CCR2 in islet and heart allograft rejection: tissue specificity of chemokine\/chemokine receptor function in vivo. J. Immunol. 172:767\u201375.","journal-title":"J. Immunol."},{"key":"1791000_CR70","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1210\/jc.2008-0396","volume":"93","author":"M Boni-Schnetzler","year":"2008","unstructured":"Boni-Schnetzler M, et al. (2008) Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J. Clin. Endocrinol. Metab. 93:4065\u201374.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1791000_CR71","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.4049\/jimmunol.166.4.2824","volume":"166","author":"ND Jones","year":"2001","unstructured":"Jones ND, et al. (2001) Differential susceptibility of heart, skin, and islet allografts to T cell-mediated rejection. J. Immunol. 166:2824\u201330.","journal-title":"J. Immunol."},{"key":"1791000_CR72","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/sj.mt.6300341","volume":"16","author":"SE Allan","year":"2008","unstructured":"Allan SE, et al. (2008) Generation of potent and stable human CD4+ T regulatory cells by activationindependent expression of FOXP3. Mol. Ther. 16:194\u2013202.","journal-title":"Mol. Ther."},{"key":"1791000_CR73","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nm1688","volume":"14","author":"O Joffre","year":"2008","unstructured":"Joffre O, et al. (2008) Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat. Med. 14:88\u201392.","journal-title":"Nat. Med."},{"key":"1791000_CR74","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1097\/TP.0b013e3181a2e295","volume":"87","author":"J Ashton-Chess","year":"2009","unstructured":"Ashton-Chess J, et al. (2009) Using biomarkers of tolerance and rejection to identify high- and low-risk patients following kidney transplantation. Transplantation. 87:S95\u20139.","journal-title":"Transplantation"},{"key":"1791000_CR75","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1681\/ASN.2007111174","volume":"19","author":"O Bestard","year":"2008","unstructured":"Bestard O, et al. (2008) Presence of FoxP3+ regulatory T cells predicts outcome of subclinical rejection of renal allografts. J. Am. Soc. Nephrol. 19:2020\u20136.","journal-title":"J. Am. Soc. Nephrol."},{"key":"1791000_CR76","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1189\/jlb.0208145","volume":"85","author":"GB Pott","year":"2009","unstructured":"Pott GB, et al. (2009) Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J. Leukoc. Biol. 85:886\u201395.","journal-title":"J. Leukoc. Biol."},{"key":"1791000_CR77","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1021\/mp800183b","volume":"6","author":"R Panakanti","year":"2009","unstructured":"Panakanti R, Mahato RI. (2009) Bipartite vector encoding hVEGF and hIL-1Ra for ex vivo transduction into human islets. Mol. Pharm. 6:274\u201384.","journal-title":"Mol. Pharm."},{"key":"1791000_CR78","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s00125-009-1349-0","volume":"52","author":"R Glas","year":"2009","unstructured":"Glas R, et al. (2009) Purinergic P2X7 receptors regulate secretion of interleukin-1 receptor antagonist and beta cell function and survival. Diabetologia. 52:1579\u201388.","journal-title":"Diabetologia"},{"key":"1791000_CR79","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.transproceed.2008.10.099","volume":"41","author":"BR Hsu","year":"2009","unstructured":"Hsu BR, et al. (2009) Interleukin-1 receptor antagonist enhances islet engraftment without impacting serum levels of nitrite or osteopontin. Transplant Proc. 41:1781\u20135.","journal-title":"Transplant Proc."},{"key":"1791000_CR80","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1073\/pnas.0915000107","volume":"107","author":"EE Ghosn","year":"2010","unstructured":"Ghosn EE, Cassado AA, Govoni GR, et al. (2010) Two physically, functionally, and developmentally distinct peritoneal macrophage subsets. Proc. Natl. Acad. Sci. U. S. A. 107:2568\u201373.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"1791000_CR81","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1164\/ajrccm.160.4.9807166","volume":"160","author":"AM Cantin","year":"1999","unstructured":"Cantin AM, Woods DE. (1999) Aerosolized prolastin suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection. Am. J. Respir. Crit. Care Med. 160:1130\u20135.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1791000_CR82","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1080\/00365540701225744","volume":"39","author":"ED Chan","year":"2007","unstructured":"Chan ED, et al. (2007) Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterium abscessus infection of macrophages. Scand. J. Infect. Dis. 39:690\u20136.","journal-title":"Scand. J. Infect. Dis."},{"key":"1791000_CR83","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1165\/ajrcmb.22.2.3809","volume":"22","author":"R Dhami","year":"2000","unstructured":"Dhami R, et al. (2000) Acute cigarette smokeinduced connective tissue breakdown is mediated by neutrophils and prevented by alpha1-antitrypsin. Am. J. Respir. Cell Mol. Biol. 22:244\u201352.","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"1791000_CR84","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.4049\/jimmunol.157.11.5126","volume":"157","author":"C Libert","year":"1996","unstructured":"Libert C, et al. (1996) Alpha1-antitrypsin inhibits the lethal response to TNF in mice. J. Immunol. 157:5126\u20139.","journal-title":"J. Immunol."},{"key":"1791000_CR85","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/15412550500493220","volume":"3","author":"JM Stocks","year":"2006","unstructured":"Stocks JM, et al. (2006) Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira. COPD. 3:17\u201323.","journal-title":"COPD"},{"key":"1791000_CR86","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1378\/chest.119.3.737","volume":"119","author":"M Wencker","year":"2001","unstructured":"Wencker M, et al. (2001) Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest. 119:737\u201344.","journal-title":"Chest"},{"key":"1791000_CR87","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1378\/chest.118.5.1480","volume":"118","author":"J Lieberman","year":"2000","unstructured":"Lieberman J. (2000) Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest. 118:1480\u20135.","journal-title":"Chest"},{"key":"1791000_CR88","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/eji.200939429","volume":"39","author":"M Herrath von","year":"2009","unstructured":"von Herrath M, Nepom GT, von Herrath MG. (2009) Remodeling rodent models to mimic human type 1 diabetes. Eur. J. Immunol. 39:2049\u201354.","journal-title":"Eur. J. Immunol."}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.crossref.org\/molmed.2011.00145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2119\/molmed.2011.00145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T09:25:14Z","timestamp":1686389114000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.2119\/molmed.2011.00145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,9]]},"references-count":88,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["1791000"],"URL":"https:\/\/doi.org\/10.2119\/molmed.2011.00145","relation":{},"ISSN":["1076-1551","1528-3658"],"issn-type":[{"value":"1076-1551","type":"print"},{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,9]]}}}